RJA
RDHL

Raymond James & Associates’s Redhill Biopharma RDHL Stock Holding History

Raymond James & Associates’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-33
Closed -$243K – 4184
2021
Q1 		$243K Sell
33
-11
-25% -$92.3K ﹤0.01% 3494
2020
Q4 		$357K Buy
44
+25
+132% +$225K ﹤0.01% 3021
2020
Q3 		$189K Buy
+19
New +$156K ﹤0.01% 3238

Other funds holding RDHL

DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM

Raymond James & Associates's RDHL Position: Q2 2021 in Review

Raymond James & Associates sold out of Redhill Biopharma (RDHL) in Q2 2021, closing a stake of 33 shares — an estimated $243K sold.

Raymond James & Associates first reported a position in RDHL in Q3 2020 and held it in 3 quarters. The position peaked at $357K in Q4 2020. 48 funds tracked by Wall St. Rank hold RDHL as of Q2 2021.

  • Raymond James & Associates reported no remaining Redhill Biopharma position as of Q2 2021 after selling out during the quarter.
  • Raymond James & Associates sold 33 Redhill Biopharma shares in Q2 2021, an estimated $243K.
  • Raymond James & Associates first reported a position in Redhill Biopharma in Q3 2020 and held it in 3 quarters.
  • Raymond James & Associates's Redhill Biopharma position peaked at $357K in Q4 2020.
  • 48 funds tracked by Wall St. Rank held Redhill Biopharma as of Q2 2021.

Based on Raymond James & Associates's 13F filing for Q2 2021, filed 11 Aug 2021.